

**Kristin Bedard, Ph.D.**  
Vice President of Biologics; Eli Lilly Oncology  
President, Mablink Biosciences

Dr. Kristin Bedard is the Vice President of Biologics, at Eli Lilly Oncology and the Site Head for the South San Francisco research organization. She also serves as the President of Mablink Biosciences, a French subsidiary focused on ADC Technology development, that is wholly owned by Eli Lilly. Her teams are responsible for the discovery and preclinical development of diverse cancer drugs including ADCs, immune stimulators and bispecific antibodies as well as large molecule technology and platform development.

Bedard has over twenty years of experience in innate immunity, cancer research and drug development and was most recently the Senior Vice President of Discovery at Sutro Biopharma, and the scientific co-founder and Chief Scientific Officer at Kineta, Inc. where she led early discovery and development programs in immunology, infectious disease and oncology. Her teams have progressed multiple antiviral and cancer medicines from discovery into clinical development including more than ten clinical candidate nominations.

Her work in innate immunity has been well published and she is the co-inventor on more than fifteen patents for novel immuno-oncology compounds, ADC biologics and methods of drug identification.

Prior to working in pharmaceuticals, Dr. Bedard was a senior fellow at the Fred Hutchinson Cancer Research Center after completing her PhD at the University of California, Irvine. Dr. Bedard volunteers her time as a board member for the Healthcare Businesswomen's Association where she received the Everest Award in 2019 for her dedication and leadership.

She has previously served as chairwoman and scientific reviewer for the National Institutes of Health small business grant division and a Scientific Advisory Board Member for several private biotech companies including Myricx Bio in Cambridge, UK and Oncosenx in Seattle, WA.